Adagio Therapeutics, Inc. (ADGI) Stock Overview
Explore Adagio Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Adagio Therapeutics, Inc. (ADGI)
Key Financials
Key Financials
Market Cap
505.7M
P/E Ratio
-12.40
EPS (TTM)
$-2.63
ROE
-0.53%
ADGI Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Adagio Therapeutics, Inc. (NASDAQ: ADGI) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Adagio Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of ADGI on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $N/A for the NASDAQ listing.
Key metrics behind Adagio Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -12.40 and a market capitalization of 505.7M. Combined with our AI analysis, these give both institutional and retail investors a clear view of ADGI on the NASDAQ.